Aradigm has announced positive top line results from a Phase IIb study of ciprofloxacin (ARD-3100) for inhalation in patients with non-cystic fibrosis bronchiectasis, a progressive lung disease.
The mutlicentre double-blind, and placebo-controlled trial randomised 95 patients into four groups, and showed a mean reduction in colony forming units per gram of sputum.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The drug was well-tolerated and no difference in adverse events was observed between the active and placebo groups.
Aradigm senior medical director Paul Bruinenberg said the 2ml dose of ARD-3100 is equipotent to the 3ml dose.
